Atara Biotherapeutics (ATRA) Change in Account Payables (2013 - 2026)
Atara Biotherapeutics' (ATRA) quarterly Change in Account Payables came in at $510000.0 in Q1 2026, up 117.1% YoY from $234918.2 in Q1 2025, and up 367.02% on a QoQ basis from -$191000.0 in Q4 2025.
Atara Biotherapeutics (ATRA) Change in Account Payables (2013 - 2026) Analysis & Trends
Atara Biotherapeutics (ATRA) has 14 years of Change in Account Payables data on file, last reported at $510000.0 in Q1 2026.
- Quarterly Change in Account Payables rose 117.1% year-over-year to $510000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$747000.0 (up 49.18% YoY) and the FY2025 annual result came in at -$4.2 million, down 717.18% from the prior year.
- Change in Account Payables advanced to $510000.0 in Q1 2026, from -$191000.0 in the prior quarter.
- In the past five years, Change in Account Payables ranged from a high of $2.5 million in Q3 2023 to a low of -$4.6 million in Q1 2022.
- A 5-year average of -$904941.2 and a median of -$894000.0 in 2023 frame the typical range for Change in Account Payables.
- Annual changes were most pronounced in 2022 — Change in Account Payables sank 1346.78% — and 2024, when it jumped 368.34%.
- Tracing ATRA's Change in Account Payables over 5 years: stood at -$4.5 million in 2022, then soared by 36.85% to -$2.8 million in 2023, then surged by 179.12% to $2.2 million in 2024, then plunged by 108.59% to -$191000.0 in 2025, then jumped by 367.02% to $510000.0 in 2026.
- The last three Change in Account Payables figures came in at $510000.0 (Q1 2026), -$191000.0 (Q4 2025), and -$983000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -66.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -8.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 37.53 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Atara Biotherapeutics | 141.08 Mn | 124.53 Mn | 439,000.00 | 187,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 187,000.00 |
| Jun 30, 2026 | 187,000.00 |
| Mar 31, 2026 | 510,000.00 |
| Mar 31, 2026 | 510,000.00 |
| Dec 31, 2025 | -191,000.00 |
| Dec 31, 2025 | -191,000.00 |
| Sep 30, 2025 | -983,000.00 |
| Sep 30, 2025 | -983,000.00 |
| Jun 30, 2025 | -83,000.00 |
| Jun 30, 2025 | -83,000.00 |
| Mar 31, 2025 | -2.98 Mn |
| Mar 31, 2025 | -2.98 Mn |
| Dec 31, 2024 | 2.22 Mn |
| Dec 31, 2024 | 2.22 Mn |
| Sep 30, 2024 | -3.11 Mn |
| Sep 30, 2024 | -3.11 Mn |
| Jun 30, 2024 | 2.40 Mn |
| Jun 30, 2024 | 2.40 Mn |
| Mar 31, 2024 | -826,000.00 |
| Mar 31, 2024 | -826,000.00 |